SALT LAKE CITY, Utah — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene” or the “Company”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced completion...
Latest News
SALT LAKE CITY, Utah — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurological diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced...
SALT LAKE CITY, Utah — Clene Inc. and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today reported new data from the 12-month long-term open...
SALT LAKE CITY, Utah — Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY...
Cleveland, Ohio – Cleveland Clinic and the University of Western Ontario have been awarded a $4.9 million grant from Helmsley Charitable Trust to build a consortium to develop clinical trial outcome tools for patients with Crohn’s disease and permanent ileostomy. A permanent ileostomy is a surgical procedure to divert stool...
CLEVELAND, Ohio – Cleveland Clinic researchers are presenting updated findings from their novel study of a vaccine aimed at preventing triple-negative breast cancer, the most aggressive and lethal form of the disease. The study team found that the investigational vaccine was generally well tolerated and produced an immune response in...
Cleveland, OH – Cleveland Clinic researchers analyzed genes and brain tissue of patients with Alzheimer’s and found that differences in brain immunometabolism – the interactions between the immune system and the ways cells create energy – may contribute to women’s increased risk for the disease and its severity. The findings,...
CLEVELAND, Ohio – New Cleveland Clinic research has mapped changes in tumor-related bacteria to uncover potential new strategies to combat the rise of young-onset colorectal cancer (CRC) in people under the age of 50. The research reveals differences in tumor-related bacteria associated with young-onset colorectal cancer. Published in eBioMedicine (part...
Cleveland, Ohio – Researchers at Cleveland Clinic are using artificial intelligence to uncover the link between the gut microbiome and Alzheimer’s disease. Previous studies showed that Alzheimer’s disease patients have changes in their gut bacteria as the disease develops. The newly published Cell Reports study outlines a computational method to...
CLEVELAND, Ohio – A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the...